NASDAQ: SRZN - Surrozen, Inc.

Lønnsomhet i seks måneder: -6.5%
Sektor: Healthcare

Kampanjeplan Surrozen, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Flere detaljer
Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

Цена ао 13.65
Выручка 0.0125
EBITDA -0.0228
P/S 1.47
P/BV 2.06
EV/EBITDA 1.28
ISIN US86889P1093
Сайт https://www.surrozen.com
Число акций ао 0.00202 млрд
Валюта usd
IPO date 2021-01-11
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Prisendring per dag: -4.37% (10.98)
Prisendring per uke: +1.64% (10.33)
Prisendring per måned: +2.54% (10.2399)
Prisendring over 3 måneder: +6.6% (9.85)
Prisendring over seks måneder: -6.5% (11.2299)
Prisendring per år: +2 254.24% (0.446)
Prisendring over 3 år: +6.92% (9.82)
Prisendring siden begynnelsen av året: +2 313.77% (0.435)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 1.35 9
P/BV 0.4458 10
P/E 0 0
EV/EBITDA 0.3831 10
Total: 6.13

Effektivitet

Navn Betydning Karakter
ROA, % -93.41 0
ROE, % -113.46 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0822 10
Total: 9.8

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 0 0
Lønnsomhet Ebitda, % 80.34 9
Lønnsomhet EPS, % 416.44 10
Total: 7.2
Flere detaljer

Institusjoner Volum Dele, %
Column Group LLC 627651 19.62
Euclidean Capital LLC 87696 2.74
Blackrock Inc. 58494 1.83
ArrowMark Colorado Holdings LLC 55123 1.72
Board Of Trustees Of The Leland Stanford Junior University 52131 1.63
Trustees Of Columbia University In The City Of New York 47930 1.5
Morgan Stanley 35211 1.1
Vanguard Group Inc 32511 1.02
Alyeska Investment Group, L.P. 20376 0.64
Geode Capital Management, LLC 11473 0.36

ETF Dele, % Lønnsomhet for året, % Utbytte, %
iShares Micro-Cap ETF 0.00519 36.318555985322 1.54048



Veileder Stillingstittel Betaling Fødselsår
Mr. Craig C. Parker M.B.A. CEO, President & Director 825.32k 1962 (62 år)
Mr. Charles Williams CFO, COO & Corporate Secretary 611.03k 1980 (44 år)
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisory Board N/A
Dr. Roeland Nusse Ph.D. Co-Founder & Member of Scientific Advisory Board N/A 1950 (74 år)
Dr. Calvin Kuo M.D., Ph.D. Co-Founder & Member of Scientific Advisor N/A
Dr. Li Yang Ph.D. Executive Vice President of Research 535.46k 1969 (55 år)
Esther Jhun Controller N/A

Adresse: United States, South San Francisco. CA, 171 Oyster Point Boulevard - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.surrozen.com